E-viri
Recenzirano
Odprti dostop
-
Planas, Delphine; Saunders, Nell; Maes, Piet; Guivel-Benhassine, Florence; Planchais, Cyril; Buchrieser, Julian; Bolland, William-Henry; Porrot, Françoise; Staropoli, Isabelle; Lemoine, Frederic; Péré, Hélène; Veyer, David; Puech, Julien; Rodary, Julien; Baele, Guy; Dellicour, Simon; Raymenants, Joren; Gorissen, Sarah; Geenen, Caspar; Vanmechelen, Bert; Wawina-Bokalanga, Tony; Martí-Carreras, Joan; Cuypers, Lize; Sève, Aymeric; Hocqueloux, Laurent; Prazuck, Thierry; Rey, Félix A; Simon-Loriere, Etienne; Bruel, Timothée; Mouquet, Hugo; André, Emmanuel; Schwartz, Olivier
Nature, 02/2022, Letnik: 602, Številka: 7898Journal Article
The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa . It has since spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of around 32 mutations in spike-located mostly in the N-terminal domain and the receptor-binding domain-that may enhance viral fitness and enable antibody evasion. Here we isolated an infectious Omicron virus in Belgium from a traveller returning from Egypt. We examined its sensitivity to nine monoclonal antibodies that have been clinically approved or are in development , and to antibodies present in 115 serum samples from COVID-19 vaccine recipients or individuals who have recovered from COVID-19. Omicron was completely or partially resistant to neutralization by all monoclonal antibodies tested. Sera from recipients of the Pfizer or AstraZeneca vaccine, sampled five months after complete vaccination, barely inhibited Omicron. Sera from COVID-19-convalescent patients collected 6 or 12 months after symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titres 6-fold to 23-fold lower against Omicron compared with those against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and, to a large extent, vaccine-elicited antibodies. However, Omicron is neutralized by antibodies generated by a booster vaccine dose.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.